Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EGb 761

Drug Profile

EGb 761

Alternative Names: GBE 761; Gingogink; Ginkgo biloba special extract - Dr Wilmar Schwabe Group/Ipsen; Tanakan; Tebonin; Tramisal

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dr. Willmar Schwabe Pharmaceuticals
  • Developer Dr. Willmar Schwabe Pharmaceuticals; Ipsen
  • Class Antiplatelets; Herbal medicines; Phytotherapies
  • Mechanism of Action Antioxidants; Nitric oxide synthase type II inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alzheimer's disease; Cognition disorders; Ear disorders; Eye disorders; Neurological disorders; Vascular disorders
  • Phase III Tinnitus
  • Phase II Vertigo
  • No development reported Friedreich's ataxia
  • Discontinued Pancreatic cancer

Most Recent Events

  • 31 May 2018 Dr Willmar Schwabe GmbH completes a phase II trial in Vertigo in Poland (PO, Tablet) (ISCRTN83227991)
  • 19 Dec 2017 Dr. William Schwabe Pharmaceuticals completes a phase II trial in Tinnitus in Poland (EudraCT2016-000315-32)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Tinnitus(Combination therapy) in Switzerland (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top